ArticleSynthetic and systems biotechnology2021
Systematic optimization of the yeast cell factory for sustainable and high efficiency production of bioactive ginsenoside compound K.
Article in Synthetic and systems biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Artificial intelligence and synthetic biology in traditional Chinese medicine: revolutionizing public health applications.Frontiers in plant science · 2026Review
- Sustainable Production of Ginsenosides: Advances in Biosynthesis and Metabolic Engineering.Plants (Basel, Switzerland) · 2025Review
- Metabolic Engineering of Terpenoid Biosynthesis in Medicinal Plants: From Genomic Insights to Biotechnological Applications.Current issues in molecular biology · 2025Review
- New Insight into Microbial Exploitation to Produce Bioactive Molecules from Agrifood and By-Products' Fermentation.Foods (Basel, Switzerland) · 2025Review
- Modulation of morphogenesis and metabolism by plant cell biomechanics: from model plants to traditional herbs.Horticulture research · 2025Article
- Recent trends in the elucidation of complex triterpene biosynthetic pathways in horticultural trees.Horticulture research · 2025Article
- Engineering UDP-Glycosyltransferase UGTPg29 for the Efficient Synthesis of Ginsenoside Rg3 from Protopanaxadiol.Applied biochemistry and biotechnology · 2025Article
- Multi-strategy ugt mining, modification and glycosyl donor synthesis facilitate the production of triterpenoid saponins.Frontiers in plant science · 2025Review
- Sustainable production of natural products using synthetic biology: Ginsenosides.Journal of ginseng research · 2024Review
- Biosynthesis and biotechnological production of the anti-obesity agent celastrol.Nature chemistry · 2023Article
- Compound K Production: Achievements and Perspectives.Life (Basel, Switzerland) · 2023Review
- Advances in the biosynthesis and metabolic engineering of rare ginsenosides.Applied microbiology and biotechnology · 2023Review
- Biotransformation of High Concentrations of Ginsenoside Substrate into Compound K by β-glycosidase fromGenes · 2023Article
- Production of a Novel Protopanaxatriol-Type Ginsenoside by Yeast Cell Factories.Bioengineering (Basel, Switzerland) · 2023Article
- Pathway elucidation of bioactive rhamnosylated ginsenosides in Panax ginseng and their de novo high-level production by engineered Saccharomyces cerevisiae.Communications biology · 2022Article
- Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3Acta pharmaceutica Sinica. B · 2022Article
- Glycosyltransferases: Mining, engineering and applications in biosynthesis of glycosylated plant natural products.Synthetic and systems biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenoside Compound K (CK) has been recognized as a major functional component that is absorbed into the systemic circulation after oral administration of ginseng. CK demonstrates diverse bioactivities. A phase I clinical study indicated that CK was a potential candidate for arthritis therapy. However, a phase II clinical study was suspended because of the high cost associated with the present CK manufacturing approach, which is based on the traditional planting-extracting-biotransforming process. We previously elucidated the complete CK biosynthetic pathway and realized for the first time
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.